• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Mylan

Mylan

Mylan NV MYL 3 Star

Last Price$48.05Day Change (%)1.33%
Open Price$46.73Day Change ($)0.63
Day Range46.55–48.3952-Week Range44.80–76.68

As of Fri 9/4/2015 5:00:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  5. Research
  1. Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo

    Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo

  2. Mylan Clarifies Certain Inaccuracies by Third Parties Related to Lowered Acceptance Condition to Acquire Perrigo

    Mylan Clarifies Certain Inaccuracies by Third Parties Related to Lowered Acceptance Condition to Acquire Perrigo

  3. Mylan Responds to ISS Recommendation Regarding Perrigo Transaction

    Mylan Responds to ISS Recommendation Regarding Perrigo Transaction

  4. Mylan Statement in Response to FDA Warning Letter Relating to Certain Agila Facilities

    Mylan Statement in Response to FDA Warning Letter Relating to Certain Agila Facilities

  5. Paulson & Co. Votes in Support of Mylan's Proposed Merger with Perrigo

    Paulson & Co. Votes in Support of Mylan's Proposed Merger with Perrigo

  6. Egan-Jones Joins Glass Lewis in Recommending Mylan Shareholders Vote For Perrigo Transaction Proposal

    Egan-Jones Joins Glass Lewis in Recommending Mylan Shareholders Vote For Perrigo Transaction Proposal

  7. Rate Hikes? Not in 2015

    Watson Pharmaceuticals WPI scored big Tuesday when the Food and Drug Administration approved the firm's generic fentanyl patch. We may modestly increase our fair value estimate for Watson and will maintain our fair value estimate for competitor Mylan Laboratories MYL . The pain patch is one of the ...

  8. What Migration Can (and Can’t) Do for a Country’s GDP

    Mylan Laboratories MYL reported impressive second-quarter results Wednesday. However, most of the improvement was temporary and will not affect our fair value estimate. The quarter was only slightly better than we expected after excluding a one-time litigation payment and proceeds from a product ...

  9. Research and Markets: Global Markets for Drug Delivery: Transdermal and Inhalation Drug Delivery Technologies in 2015

    Research and Markets: Global Markets for Drug Delivery: Transdermal and Inhalation Drug Delivery Technologies in 2015

  10. Proxy Adviser Says Mylan Holders Should Shun Perrigo Deal

    Proxy Adviser Says Mylan Holders Should Shun Perrigo Deal

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.